The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Official Title: A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer
Study ID: NCT02857270
Brief Summary: The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Georgetown University Medical Center, Washington, District of Columbia, United States
Florida Cancer Specialists, Sarasota, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Sarah Cannon Cancer Center, Nashville, Tennessee, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
St Vincent's Hospital, Sydney, New South Wales, Australia
Linear Clinical Research Ltd, Nedlands, Western Australia, Australia
Gustave Roussy, Villejuif Cedex, , France
Shizuoka Cancer Center, Sunto-Gun, Shizuoka, Japan
National Cancer Center Hospital, Chuo-ku, Tokyo, Japan
Name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Affiliation: Eli Lilly and Company
Role: STUDY_DIRECTOR